Treatment of autism with cannabidiol

10568,848

16/411248

May 14, 2019

The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.

ZYNERBA PHARMACEUTICALS, INC. (Devon, PA, US)

ZYNERBA PHARMACEUTICALS, INC. (Devon, PA, US)

1. A method of treating a human suffering from an autism spectrum disorder comprising: transdermally administering via a gel or cream a therapeutically effective amount of purified cannabidiol to the human suffering from the autism spectrum disorder to effectively treat the autism spectrum disorder in the human in need thereof.

2. The method of claim 1 , wherein the cannabidiol is (−)-cannabidiol.

3. The method of claim 1 , wherein the therapeutically effective amount of cannabidiol is 250 mg total daily.

4. The method of claim 1 , wherein the therapeutically effective amount of cannabidiol is 500 mg total daily.

5. The method of claim 1 , wherein the cannabidiol is formulated as a permeation-enhanced gel.

6. The method of claim 1 , wherein the cannabidiol is administered in a single-daily dose.

7. The method of claim 1 , wherein the cannabidiol is administered in two daily doses.

8. The method of claim 1 , wherein the therapeutically effective amount of cannabidiol is between about 50 mg to 500 mg total daily.

8293786 October 2012 Stinchcomb et al.
8435556 May 2013 Stinchcomb et al.
8449908 May 2013 Stinchcomb et al.
9375417 June 2016 Smith et al.
9447019 September 2016 Mechoulam et al.
9533942 January 2017 Stinchcomb et al.
9675656 June 2017 Crowley
9730911 August 2017 Verzura et al.
9782360 October 2017 Mechoulam et al.
2008/0139472 June 2008 Lauterborn et al.
2010/0273895 October 2010 Stinchcomb et al.
2011/0052694 March 2011 Stinchcomb et al.
2015/0342902 December 2015 Vangara et al.
2015/0343071 December 2015 Vangara et al.
2016/0022627 January 2016 Smith
2016/0256410 September 2016 Aung-Din
2016/0256411 September 2016 Aung-Din
2016/0271252 September 2016 Vangara et al.
2016/0338974 November 2016 Aung-Din
2017/0224634 August 2017 Vangara et al.
2017/0274030 September 2017 Crowley
2017/0360745 December 2017 Blackmon et al.
2018/0140560 May 2018 De Vries et al.
2010/127033 November 2010
2016109624 July 2016
2017149387 September 2017
2017151980 September 2017
2017158539 September 2017
2017178807 October 2017
2017178810 October 2017
2017182950 October 2017
2018002637 January 2018
2018109471 June 2018

Banks S, O'Neill C, Sebree T. Pharmacokinetic Evaluation of Subcutaneously Administered ZYN001 in Male Sprague-Dawley Rats. PAINWeek. Sep. 8-12, 2015. cited by applicant
Bergmaschi et al., Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naiver Social Phobia Patients, Neuropsychopharmacology (2011) 36, 1219-1226. cited by applicant
Blessing et al., Cannibidiol as a Potential Treatment for Anxiety Disorders, Neurotherapeutics, Oct. 2015, 12(4): 825-836. cited by applicant
Bonn-Miller M, Banks SL, Sebree T. Conversion of Cannabidiol Following Oral Administration: Authors' Response to Grotenhermen et al. Cannabis and Cannabinoid Research 2017;2:1, 5-7. cited by applicant
Bonn-Miller M, Gutterman D. A Permeation-Enhanced Synthetic Cannabidiol (CBD) Transdermal Gel for the Treatment of PTSD. Military Health System Research Symposium. Orlando, FL. Aug. 15-18, 2016. cited by applicant
Bonn-Miller M, Sebree T, O'Neill C, Messenheimer J. Neuropsychological Effects of ZYN002 (Synthetic Cannabidiol) Transdermal Gel in Healthy Subjects and Patients with Epilepsy: Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies. American Epilepsy Society Annual Meeting. Houston, TX. Dec. 2-6, 2016. cited by applicant
Fusar-Poli, et al., “Modulation of Effective Connectivity During Emotional Processing by D9-tetrahydrocannabinol and Cannabidiol,” International Journal of Neuropsychopharmacology (2010) 13, 421-432. cited by applicant
Gauvin D, O'Neill C, Patterson DR. Respiratory Evaluation of Subcutaneously Administered ZYN001 in Male Sprague-Dawley Rats. PAINWeek. Sep. 8-12, 2015. cited by applicant
Jung KM, Sepers M, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 2012;3:1080. cited by applicant
Kidd, et al., Cannabinoids in the Treatment of Autism Spectrum Disorder: Demanding Data Before Using Fad Therapies, Pediatric Neurology, 88 (2018) 10-11. cited by applicant
Lozano, et al., “Advances in the Understanding of Gabaeric Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder,” Curr Pharm Des Author manuscript, (2015); 21 (34): 4972-4979. cited by applicant
Merrick J, Lane B, Sebree T, Yaksh T, O'Neill C, Banks SL. Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid. Cannabis and Cannabinoid Research 2016;1:1, 102-112, DOI: 10.1089/can.2015.0004. cited by applicant
Novagant Corp. Announces Breakthrough in Cannabidiol (CBD) Transdermal Patch for Localized Delivery, Oct. 29, 2014. cited by applicant
O'Brien T MD, FRACP; Berkovic, S, MD, FRACP; French, J, MD, et al. Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy in Adults. 2017 American Epilepsy Society Annual Meeting, Washington, DC. Dec. 1-5, 2017. cited by applicant
Paudel KS, Hammell DC, et al. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Development and Industrial Pharmacy 2010;36(9):1088-1097. cited by applicant
Qin M, Zeidler Z, et al. Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome. Behav Brain Res Sep. 15, 2015;291:164-71. cited by applicant
Salgado, et al., Autism Spectrum Disorder and Cannabidiol: Have We Seen This Movie Before?, Global Pediatric Health, vol. 5:1-5 (2018). cited by applicant
Sativex Product Monograph, Buccal Spray, Mar. 30, 2012 (55 pages). cited by applicant
Sebree T, O'Neill C, Messenheimer J, Gutterman D. Safety and Tolerability of ZYN002 (Synthetic Cannabidiol) Transdermal Permeation-Enhanced Gel in Healthy Subjects and Epilepsy Patients: Three Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies. American Epilepsy Society Annual Meeting. Houston, TX. Dec. 2-6, 2016. cited by applicant
Wei, et al., Enhancement of Anandamide-Mediated Endocannabinoid Signally Corrects Autism-Related Social Impairment, Cannabis and Cannabinoid Research, vol. 1.1 (2016). cited by applicant
Wheeler, et al., “Anxiety, Attention Problems, Hyperactivity, and the Aberrant Behavior Checklist in Fragile X Syndrome,” American Journal of Medical Genetics, (2013) 141-155. cited by applicant
Winton-Brown, et al., “Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMR1 Study,” Neuropsychopharmacology (2011) 36, 1340-1348. cited by applicant
Hadland, S., et al., “Medical Marijuana: Review of the Science and Implications for Developmental Behavioral Pediatric Practice,” J Dev Behav Pediatr. 2015 ; 36(2): 115-123. cited by applicant
Aran, A., et al., “Cannabidiol Based Medical Cannabis in Children with Autism—a Retrospective Feasibility Study (P3.318),” Neurology, 90:15 Supplement, (2018). cited by applicant

edspgr.10568848